https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/neurocognitive

The Latest

hole in a fence

This Week in HIV Research: Removing Barriers to Better Care

Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.

Dual Maintenance Therapy With Dolutegravir + Rilpivirine Img

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

Promo Image

This Week in HIV Research: This Is Your Brain on (HIV) Drugs

NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.